Inflammasomes and Atherosclerosis: a Mixed Picture

Circ Res. 2023 May 26;132(11):1505-1520. doi: 10.1161/CIRCRESAHA.123.321637. Epub 2023 May 25.

Abstract

The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent activation of the NLRP3 inflammasome requires a second hit such as defective cholesterol efflux, defective DNA repair, clonal hematopoiesis or diabetes. Similarly in humans some mutations promoting clonal hematopoiesis increase coronary artery disease risk in part by promoting inflammasome activation. Recent studies in mice and humans point to a wider role of the AIM2 (absent in melanoma 2) inflammasome in promoting cardiovascular disease including in some forms of clonal hematopoiesis and diabetes. These developments suggest a precision medicine approach in which treatments targeting inflammasomes or IL-1β might be best employed in clinical settings involving increased inflammasome activation.

Keywords: cardiovascular diseases; clonal hematopoiesis; diabetes; inflammasomes; interleukin 1β; macrophages; mouse models.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atherosclerosis* / genetics
  • Cardiovascular Diseases*
  • Humans
  • Inflammasomes / genetics
  • Interleukin-1beta
  • Mice
  • NLR Family, Pyrin Domain-Containing 3 Protein / genetics
  • Thrombosis*

Substances

  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Interleukin-1beta